AzTrials
AzTrials

DiabetesHistaHeatNCT05921097

Comparison of Histamine and Local Heating for Evoking the Axon-reflex Flare Response in Diabetes

An observational study of Diabetes and Diabetes Mellitus, Type 1, run by Aalborg University Hospital at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Diabetic peripheral neuropathy is the most common complication to diabetes mellitus affecting as much as 50% of the population with diabetes. Symmetrical sensory neuropathy is by far the most common pattern, which often progress slowly over many years, although some individuals experience faster and more severe… Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
Histamin-induced axon-reflex flare response, Local heating-induced axon-reflex flare response and 2-point discrimination tasks
How many people
40 participants
Where
1 siteDenmark
Study dates
17 Jun 2023to 29 Jul 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • Adult, Older adult

Study population: People with T1DM

Who may be able to join

  • Age 18-75 years and diagnosed with type 1 diabetes

Who cannot join

  • Known critical limb ischemia (ankle-brachial index < 50 mmHg or toe-brachial index < 30 mmHg)
  • Symptoms of claudicatio intermittens
  • Inability to do without antihistamine for 24h prior to examination
  • Known neurological disease (e.g., multiple sclerosis)
  • Severe skin diseases on either foot (e.g., fulminant pemphigoid)
  • Previous or current alcohol or drug abuse
Show all 13Show fewer
  • Previous or current chemotherapy or current disseminated cancer
  • Known cause of neuropathy other than diabetes
  • Previous amputation on either foot
  • Active diabetic foot ulcer on either foot
  • Pregnancy
  • Inability to participate or other condition thought to impact the results (evaluated by investigator)
  • Asymmetrical neuropathy (i.e., previous accident with radiating pain)

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Aalborg University Hospital

    Aalborg, 9000

Other trials in Denmark

About this study

Diabetic peripheral neuropathy is the most common complication to diabetes mellitus affecting as much as 50% of the population with diabetes. Symmetrical sensory neuropathy is by far the most common pattern, which often progress slowly over many years, although some individuals experience faster and more severe courses. Despite the frequent occurrence, the causes of diabetic peripheral neuropathy are largely unknown, which is reflected in the fact that no disease-modifying treatments are available for preventing, treating or even halting the progression of the disease. The consequences can be dire, as neuropathy frequently leads to foot ulcers, amputations or intolerable neuropathic pain in the lower extremities. Sensory loss may go completely undetected in diabetes, as there often are literally no symptoms. For many individuals, the development of diabetic peripheral neuropathy can therefore proceed completely unnoticed, making regular screening the most important tool for diagnosing the condition. Unfortunately, unlike nephropathy or retinopathy, diabetic peripheral neuropathy is not easily screened for, as the condition lacks reliable markers for early- or progressing disease. Therefore, screening for diabetic peripheral neuropathy currently revolves around diagnosing loss of protective sensation, judged by the inability to feel vibration or light touch. However, in their most recent guidelines, the American Diabetes Association has included screening for small fibre neuropathy using either the cold- and heat perception thresholds or pinprick as a clinical standard. Although this acknowledgement of the importance of assessing not only large- but also small nerve fibres is a huge step towards early detection of diabetic peripheral neuropathy, the overriding issue of insensitive, unreproducible, and inaccurate bedside tests for small nerve fibres remains. While cold- and heat perception and pinprick sensation are indeed mediated by small nerve fibres, the sensitivity of these methods, outside of extreme standardization only achievable in dedicated neuropathy research-centres, remain poor and not usable on an individual level. This lack of sensitivity has also become apparent in several large clinical trials, where the methods have continuously failed as robust clinical endpoints. Due to this, the hunt for a sensitive and reproducible method for adequate assessment of the small nerve fibres have begun. Amongst several interesting methods, two have gained particular interest (corneal confocal microscopy and skin biopsies with quantification of intra-epidermal nerve fiber density), due to their diverse strengths, although clinical application is currently limited to a few specialized sites. Furthermore, both methods suffer several inherent issues including that fact that they only provide information about the structure of the nerves and not the function. One method to assess the function of small cutaneous C-fibers is the assessment of the axon reflex flare response using laser doppler imaging (LDI) or Full-field laser perfusion imaging (FLPI), which has classically been studied using local heating. Unfortunately, this method is limited in clinical usage due to time-consumption. The investigators recently published an alternative method using a simple skin-prick application of histamine to evoke the response, which reduced the examination-time markedly. Before claiming the method to be a better alternative, the investigators do however need to prove that the method is as good as the original.

In addition to the direct comparison of the histamine-induced and the heating-induced axon-reflex flare response the study will also assess spatial acuity in the same cohort as a secondary aim. Spatial acuity is considered as a measure of the sensory systems ability to code spatial information regarding an external stimulus. To investigate the spatial acuity, the 2-point discrimination task (2PDT) is often used. Spatial acuity has been shown to be impaired in several chronic pain condition. Additionally, it has been shown that the 2PDT may be a useful tool to understand the sensory changes in diabetes[8].

Being tested
Histamin-induced axon-reflex flare response, Local heating-induced axon-reflex flare response, 2-point discrimination tasks, NC-Stat DPNCheck, QST
Keywords
Diabetes, Neuropahty
Medical subject headings
Diabetes Mellitus, Diabetes Mellitus, Type 1, Small Fiber Neuropathy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Histamin-induced axon-reflex flare responseDiagnostic test

    Histamin-induced axon-reflex flare response

  • Local heating-induced axon-reflex flare responseDiagnostic test

    Local heating-induced axon-reflex flare response

  • 2-point discrimination tasksDiagnostic test

    2-point discrimination tasks

  • NC-Stat DPNCheckDiagnostic test

    NC-Stat DPNCheck

  • QSTDiagnostic test

    Also called Quantitative Sensory Testing, thermal

    QST

  • BiothesiometryDiagnostic test

    Also called VPT

    Biothesiometry

Study groups in NCT05921097
Study groupRoleWhat they receive
T1DMPeople with type 1 diabetes
Receives: Diagnostic Test: Histamin-induced axon-reflex flare response; Diagnostic Test: Local heating-induced axon-reflex flare response; Diagnostic Test: 2-point discrimination tasks; Diagnostic Test: NC-Stat DPNCheck; Diagnostic Test: QST; Diagnostic Test: Biothesiometry

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison of histamine and local heating (area size)

    The evoked area (assessed by full-field laser speckle perfusion imaging) by histamine and local heating will be compared as a proxy for small fiber neuropathy in diabetes

    Measured: Through study completion, an average of 1-2 years

  2. Comparison of axon-reflex flare responses with QST

    Comparison of axon reflex flare responses with an established method (area size vs cold and heat detection threshold)

    Measured: Through study completion, an average of 1-2 years

Secondary outcomes (2)
  1. 2PDT in diabetes with and without DPN

    Assess spatial acuity through 2PDT in people with diabetes with and without DPN.

    Measured: Through study completion, an average of 1-2 years

  2. Comparison of axon-reflex flare responses with NC-Stat DPNCheck

    Comparison of axon reflex flare responses with an established method (sural nerve conduction velocity/amplitude)

    Measured: Through study completion, an average of 1-2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jun 2023
  2. Study start17 Jun 2023
  3. Primary completion17 Jun 2024
  4. Study completion29 Jul 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05921097
Sponsor's protocol ID
N-20230007
Acronym
HistaHeat
Status last verified
Jul 2024
First submitted
7 Jun 2023
Last updated
30 Jul 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes and Diabetes Mellitus, Type 1, run by Aalborg University Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparison of histamine and local heating (area size) (time frame: Through study completion, an average of 1-2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in